Floatz logo

Balstilimab

Rectal Cancer

City of Hope Medical Centermonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

69 Active assets in the Rectal Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
Sun Yat-sen University
Phase 4BBB
FLUOROURACILUM
Seoul National University Hospital
Phase 3BBB
Eloxatin
Sun Yat-sen University
Phase 3BBB
Capecitabine
Tao Zhang
Phase 3BB
Cetuximab
Fudan University
Phase 3BB

View all 50 →

Same molecule, other indications

Balstilimab is also rated in:

colorectal adenocarcinomaDormant
BB
Indicative ·
66 / 100
View asset →
Metastatic Colorectal AdenocarcinomaDormant
B
Indicative ·
62 / 100
View asset →
colorectal carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →